GlassScriptPhysician profile
Yao Liu
NPI 1891798971
$2,146.09
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $1,041 · 2021: $487 · 2022: $41.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $539.74 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $251.29 | 2019-2021 | |
| Allergan, INC. | $237.02 | 2019-2021 | |
| Biogen, INC. | $223.51 | 2020-2021 | |
| Abbvie INC. | $157.13 | 2021-2022 | |
| Lilly USA, LLC | $138.94 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $112.03 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $96.58 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $65.09 | 2019 | |
| Ucb, INC. | $59.02 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $47.03 | 2019-2020 | |
| Lundbeck LLC | $39.98 | 2019-2020 | |
| Eisai INC. | $36.68 | 2019 | |
| Emd Serono, INC. | $23.60 | 2020 | |
| Mallinckrodt Hospital Products INC. | $22.25 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $21.01 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.96 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.54 | 2021 | |
| Pfizer INC. | $18.28 | 2021 | |
| Amgen INC. | $17.41 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yao Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.